Overview

Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response

Status:
Unknown status

Trial end date:
2021-10-10

Target enrollment:

Participant gender:

Summary

The study purpose is to test the hypothesis that Chronic Phase Chronic Myeloid Leukemia (CP-CML) patients with stable Complete Molecular Response (CMR) who discontinue Dasatinib treatment are able to maintain a sustained remission in the long-term, with undetectable or minimally detectable BCR-ABL residual disease.

Phase:

Phase 2

Details

Lead Sponsor:

Bristol-Myers Squibb

Collaborators:

European Organisation for Research and Treatment of Cancer - EORTC
ICON plc
Molecular MD
MultiPharma
PPD
Steering Committee

Treatments:

Dasatinib